Forest Laboratories clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 168 studies whose lead sponsor is Forest Laboratories. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 28, 2020.

Studies

Recruiting first, then most recently updated. Showing 50 of 168. List all 168 → · All AbbVie studies →

• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With ConstipationTerminatedNCT02559817Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide TherapeuticallyCompletedNCT02220348Phase 1

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive DisorderCompletedNCT02431806Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting GlucoseCompletedNCT00673790Phase 4

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal PainTerminatedNCT01159119Phase 1

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive DisorderCompletedNCT01085812Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive DisorderCompletedNCT01878292Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety DisorderCompletedNCT01629966Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety DisorderCompletedNCT01766401Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety DisorderCompletedNCT01844115Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)CompletedNCT02372799Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00671073Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Study of Vilazodone in Pediatric Patients With Major Depressive DisorderCompletedNCT02436239Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative ProctitisTerminatedNCT01016262Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)CompletedNCT01715805Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Study of Cariprazine in Patients With Chronic Stable SchizophreniaCompletedNCT00839852Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic ConstipationCompletedNCT02590432Phase 4

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive DisorderCompletedNCT01838876Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Long-term Study of Cariprazine in Patients With SchizophreniaCompletedNCT01104792Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)CompletedNCT02559570Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Long-term Safety and Tolerability of Cariprazine for Bipolar I DisorderCompletedNCT01059539Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of SchizophreniaCompletedNCT00694707Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for HypertensionTerminatedNCT00547300Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Milnacipran in Pediatric Patients With Primary FibromyalgiaTerminatedNCT01328002Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With MemantineCompletedNCT01592747Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer PainCompletedNCT02270983Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I DisorderCompletedNCT02670538Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive DisorderCompletedNCT00854100Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationCompletedNCT00765999Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I DepressionCompletedNCT02670551Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine in SchizophreniaCompletedNCT01104779Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine in Patients With SchizophreniaCompletedNCT01104766Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive DisorderCompletedNCT02288325Phase 4

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar DepressionCompletedNCT00852202Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaCompletedNCT01412060Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar DepressionCompletedNCT01396447Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderCompletedNCT01469377Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)CompletedNCT00644358Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Diafert for Embryo Selection and Fertility ImprovementCompletedNCT02586272Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Diafert for Embryo Selection and Fertility Improvement (DESTINy)CompletedNCT02593513Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Diafert® for Embryo Selection and Fertility ImprovementCompletedNCT02593461Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst StageCompletedNCT02788617

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With CancerTerminatedNCT02732327Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine for ManiaCompletedNCT01058096Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute ManiaCompletedNCT00488618Phase 2

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Safety and Efficacy of Cariprazine for Bipolar I DisorderCompletedNCT01058668Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal ClearanceCompletedNCT01624246Phase 1

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mgTerminatedNCT01358708Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• PR-018: An Open-Label, Safety Extension of Study PR-011CompletedNCT01131507Phase 4

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie

• Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)CompletedNCT00513682Phase 3

  Sponsor listed in the registry: Forest Laboratories · First submitted before Forest Laboratories became part of AbbVie